Radioactive iodine sits at the center of this dementia and brain health question.
Radioactive iodine accumulates in the thyroid gland because the thyroid actively takes up iodine from the bloodstream to produce essential hormones. The thyroid needs iodine to make thyroxine (T4) and triiodothyronine (T3), which regulate metabolism and many bodily functions. To do this, thyroid cells use a specialized protein called the sodium-iodide symporter (NIS) that transports iodide ions from the blood into the thyroid tissue.
When radioactive iodine, such as Iodine-123 or Iodine-131, enters the body—usually through oral administration—it behaves chemically like normal stable iodine. The NIS does not distinguish between radioactive and non-radioactive forms; it transports both into the thyroid cells with equal efficiency. This means that radioactive iodine is concentrated in the gland just as stable iodine would be.
Once inside, radioactive iodine participates in normal hormone synthesis pathways within thyroid cells. However, because it emits radiation during its decay process—gamma rays for imaging isotopes like I-123 or beta particles for therapeutic isotopes like I-131—it can be detected by medical imaging devices or used to destroy overactive or cancerous thyroid tissue.
The accumulation process begins with active transport: NIS proteins on follicular cell membranes pull iodide ions against their concentration gradient using energy derived from sodium gradients maintained by cellular pumps. This ensures high concentrations of iodide inside these cells compared to blood levels.
After uptake:
1. The iodide is transported into follicular lumen spaces where it undergoes oxidation.
2. It binds to tyrosyl residues on thyroglobulin molecules forming monoiodotyrosine (MIT) and diiodotyrosine (DIT).
3. These combine enzymatically to form T3 and T4 hormones stored in colloid until released into circulation.
Because radioactive isotopes mimic this pathway exactly, they become trapped within these hormone precursors temporarily before either being incorporated into hormones or decaying radioactively within the gland.
This selective uptake explains why radioactive iodine therapy is effective for treating hyperthyroidism and certain types of thyroid cancer: administering a dose of radioactive iodide leads to its concentration specifically in abnormal or overactive parts of the gland where it delivers localized radiation damage while sparing most other tissues.
In addition, saturating patients with non-radioactive stable iodine prior to exposure can block further uptake by filling all available transport sites—a protective measure used after nuclear accidents involving radioiodines—to prevent harmful accumulation in healthy individuals’ glands.
The entire mechanism hinges on:
– The body’s physiological need for iodine,
– The presence of highly efficient sodium-iodide symporters,
– And biochemical pathways that incorporate iodide directly into hormone production,
which together cause any form of circulating iodide—including radioactive variants—to accumulate preferentially inside thyroid tissue rather than elsewhere in significant amounts.
Thus, understanding how this natural biological system works allows clinicians both diagnostic insight via imaging techniques detecting gamma emissions from accumulated radioisotopes and therapeutic control through targeted destruction of diseased tissue using beta-emitting radioiodines administered orally but concentrated precisely where needed—the very heart of modern nuclear medicine approaches targeting diseases affecting this small but vital endocrine organ.
For more, see Alzheimer’s Association — medical tests.
